SC 13G | 2018-02-14 | RENAISSANCE TECHNOLOGIES LLC | Adverum Biotechnologies, Inc. | 2,554,677 | 5.7% | EDGAR |
SC 13G/A | 2018-02-12 | Bpifrance Participations SA | Adverum Biotechnologies, Inc. | 1,345,685 | 2.8% | EDGAR |
SC 13G/A | 2018-02-01 | WILF ZYGMUNT | Adverum Biotechnologies, Inc. | - | - | EDGAR |
SC 13G | 2017-12-06 | HIGHBRIDGE CAPITAL MANAGEMENT LLC | Adverum Biotechnologies, Inc. | 2,500,000 | 5.6% | EDGAR |
SC 13G | 2017-11-27 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Adverum Biotechnologies, Inc. | 2,500,000 | 5.6% | EDGAR |
SC 13G/A | 2017-10-10 | FMR LLC | Adverum Biotechnologies, Inc. | 1,572,286 | 3.6% | EDGAR |
SC 13G | 2017-05-11 | Bpifrance Participations SA | Adverum Biotechnologies, Inc. | 2,640,775 | 6.3% | EDGAR |
SC 13G/A | 2017-02-14 | FMR LLC | Adverum Biotechnologies, Inc. | 3,706,402 | 8.9% | EDGAR |
SC 13G/A | 2017-02-13 | CADIAN CAPITAL MANAGEMENT, LP | Adverum Biotechnologies, Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2017-02-09 | Man Group plc | Adverum Biotechnologies, Inc. | 1,235,345 | 3.0% | EDGAR |
SC 13G/A | 2017-01-23 | WILF ZYGMUNT | Adverum Biotechnologies, Inc. | - | - | EDGAR |
SC 13G/A | 2016-06-10 | FMR LLC | Adverum Biotechnologies, Inc. | 3,850,486 | 9.3% | EDGAR |
SC 13D | 2016-05-18 | Versant Ventures IV, LLC | Adverum Biotechnologies, Inc. | 7,003,892 | 17.0% | EDGAR |
SC 13G/A | 2016-03-10 | BlackRock Inc. | Avalanche Biotechnologies, Inc. | 1,269,714 | 4.9% | EDGAR |
SC 13G/A | 2016-02-16 | Flynn James E | Avalanche Biotechnologies, Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2016-02-12 | FMR LLC | Avalanche Biotechnologies, Inc. | 3,863,899 | 15.0% | EDGAR |
SC 13G | 2016-02-12 | CADIAN CAPITAL MANAGEMENT, LP | Avalanche Biotechnologies, Inc. | 1,529,537 | 5.9% | EDGAR |
SC 13G/A | 2016-02-11 | INTEGRATED CORE STRATEGIES (US) LLC | Avalanche Biotechnologies, Inc. | 83,990 | 0.3% | EDGAR |
SC 13G/A | 2016-02-05 | WILF ZYGMUNT | Avalanche Biotechnologies, Inc. | - | - | EDGAR |
SC 13G | 2016-01-28 | BlackRock Inc. | Avalanche Biotechnologies, Inc. | 1,323,414 | 5.1% | EDGAR |